Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 115 clinical trials
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum tolerated dose of JNJ-67856633 in participants with relapsed/ refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

lymphoid leukemia
chronic lymphocytic leukemia
beta human chorionic gonadotrophin
leukemia
lymphoma
  • 102 views
  • 28 Jun, 2022
  • 45 locations
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS 7)

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with gemcitabine, lenalidomide, polazutumab vedotin, or umbralisib, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.

refractory b-cell non-hodgkin lymphoma
cancer
marginal zone lymphoma
measurable disease
follicular lymphoma
  • 0 views
  • 27 Jun, 2022
  • 10 locations
HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in MI Patients

Background: Potent antithrombotic therapy has improved prognosis for patients with acute myocardial infarction (MI) significantly, however, at a price of increased bleeding risk. Helicobacter pylori (H. pylori) infection commonly causes upper gastrointestinal bleeding (UGIB). If systematic screening for H. pylori and subsequent eradication therapy significantly reduces the risk of UGIB …

heart failure
stroke
fasting
myocardial infarction
infarct
  • 0 views
  • 01 Dec, 2021
  • 35 locations
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).

chronic lymphocytic leukemia
refractory lymphoma
marginal zone lymphoma
leukemia
waldenstrom's macroglobulinemia
  • 0 views
  • 24 Mar, 2022
  • 15 locations
Obinutuzumab in Marginal Zone Lymphoma

For marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy are widely used for those patients who fail local therapy or do not qualify for such. Depending on the

ct scan
splenic marginal zone lymphoma
measurable disease
large b-cell lymphoma
diffuse large b-cell lymphoma
  • 25 views
  • 08 Feb, 2022
  • 14 locations
Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma

This trial studies how well ultra low-dose radiation therapy works in treating patients with stage I-IV stomach mucosa-associated lymphoid tissue (MALT) lymphoma. Ultra low-dose radiation

  • 0 views
  • 09 Feb, 2022
  • 1 location
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past. The study will also

measurable disease
gastric malt lymphoma
ct scan
rituximab
  • 46 views
  • 29 Nov, 2021
  • 13 locations
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

first-line treatment for patients with marginal zone lymphoma.

bortezomib
cyclophosphamide
rituximab
prednisone
  • 0 views
  • 23 Aug, 2021
  • 1 location
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

This study will help researchers understand how effective the combination of venetoclax and rituximab is in treating MZL in people who have not received a previous treatment for their cancer.

  • 0 views
  • 18 Mar, 2022
  • 7 locations
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

For marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy is widely used for those patients who fail local therapy or do not qualify for such. Depending on the MZL

  • 0 views
  • 12 Mar, 2022
  • 6 locations